Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: A meta-analysis

American Journal of Cardiovascular Drugs

Volumn 12, Issue 5, 2012, Pages 335-344

  Wang, Long ^a   Zhao, Jian Wei ^a   Liu, Bing ^b   Shi, Duo ^a   Zou, Zui ^c   Shi, Xue Yin ^c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b AIR FORCE GENERAL HOSPITAL   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin type 1 receptor antagonists; antihypertensives; candesartan cilexetil; irbesartan.; losartan; meta analysis; olmesartan medoxomil; valsartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; IRBESARTAN; LOSARTAN; OLMESARTAN; VALSARTAN;

BLOOD PRESSURE REGULATION; COMPARATIVE EFFECTIVENESS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; HUMAN; HYPERTENSION; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; IMIDAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETRAZOLES; TREATMENT OUTCOME;

EID: 84866326463     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11597390-000000000-00000     Document Type: Review

References (37)

1. Wilkins K, Campbell NR, Joffres MR, et al. Blood pressure in Canadian adults. Health Rep 2010 Mar; 21 (1): 37-46
2. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007 Aug 18; 370 (9587): 591-603
3. Theodoratou D, Maniadakis N, Fragoulakis V, et al. Analysis of published economic evaluations of angiotensin receptor blockers. Hellenic J Cardiol 2009 Mar-Apr; 50 (2): 105-18
4. Catanzaro DF, Frishman WH. Angiotensin receptor blockers for management of hypertension. South Med J 2010 Jul; 103 (7): 669-73
5. Scott LJ, McCormack PL. Olmesartan medoxomil: A review of its use in the management of hypertension. Drugs 2008; 68 (9): 1239-72
6. Zhang YW, Ding R, Wu ZG. The effects and safety of mild and moderate primary hypertension treated with olmesartan medoxomil. World Clinical Drugs 2006; 27 (10): 585-8
7. Jing S, Sun NL, Ke YN. Effects and safety of mild and moderate primary hypertension treated with olmesartan medoxomil tablet. Chin J Clin Pharmaco 2006; 22 (1): 3-6
8. Giles TD, Oparil S, Silfani TN, et al. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich) 2007 Mar; 9 (3): 187-95
9. Fogari R, Zoppi A, Mugellini A, et al. Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy. Adv Ther 2006 Sep-Oct; 23 (5): 680-95
10. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996 Feb; 17 (1): 1-12
11. Zou Z, Xu F, Wang L, et al. Antihypertensive and renoprotective effects of trandolapril/verapamil combination: A meta-analysis of randomized controlled trials. J Hum Hypertens 2010; 25 (3): 203-10
12. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality ofReporting ofMeta-analyses. Lancet 1999Nov 27; 354 (9193): 1896-900
13. Higgins JPT Green S, editors. Cochrane handbook for systematic reviews of interventions, version 5.0.2. September 2009. The Cochrane Collaboration, 2009
14. Lv Y, Zou Z, Chen G, et al. Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: A meta-analysis of randomized controlled trials. Blood Press Monit 2010; 15 (4): 195-204
15. Hu YR, Chen SX, Zhang J. Efficacy and safety of domestic olmesartan in treatment of mild to moderate essential hypertension. J Shanghai Jiaotong Univ (Medical Science) 2009; 29 (11): 1359-62
16. He CZ, Lei XG, Zeng ZY. Efficacy of domestic olmesartan in treatment of mild to moderate essential hypertension. Guangxi Med Univ 2008; 25 (6): 922-3
17. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001 Sep-Oct; 3 (5): 283-91, 318
18. Giles T, Oparil S. Comparison of ascending doses of olmesartan medoxomil (o), losartan potassium (l) and valsartan (v) in patients (pts) with essential hypertension (htn). Am J Hypertens 2005; 18 (5): A56-60
19. Kong Y, CHu SL, Du J. Efficacy and safety of olmesartan medoxomil in patients with mild to moderate essential hypertension. J Shanghai Jiaotong Univ (Medical Science) 2008; 28 (2): 180-2
20. Zhu JR, Cai NS, Fan WH, et al. Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension [in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi 2006 Oct; 34 (10): 877-81
21. Hao TL, Zhang YZ. Effects of Olmesartan M edoxomil in Patients with Primary Hypertension and Left Ventricular Hypertrophy. Journal of Medical Forum 2010; 31 (1): 12-4, 7
22. Liu XF. Effects of mild and moderate primary hypertension treated with olmesartan. China modern doctor 2009; 47 (18): 228-31
23. Xi L, Tian F. Antihypertensive efficacy and safety of olmesartan monotherapy in isolated systolic hypertension. Chinese journal of integrative medicine on cardio-/cerebrovascular disease 2009; 7 (12): 1391-2
24. Brunner HR, Arakawa K. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. Clin Drug Investig 2006; 26 (4): 185-93
25. Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: A comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005; 5 (1): 41-50
26. He RM, Luo XY, Cao JM, et al. Antihypertensive efficacy and safety of domestic olmesartan monotherapy in mild or moderate essential hypertension. Shanghai Med J 2007; 30 (4): 245-51
27. Tsutamoto T, Nishiyama K, Yamaji M, et al. Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. Hypertens Res 2010 Feb; 33 (2): 118-22
28. Destro M, Scabrosetti R, Vanasia A, et al. Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: Results of 24-hour ambulatory blood pressure monitoring. Adv Ther 2005 Jan-Feb; 22 (1): 32-43
29. Li W, Chen XL, Guan SM. Clinical efficacy and safety of olmesartan medoxomil in patients with mild to moderate primary hypertension. J Clin Cardiol (China) 2008; 24 (10): 737-9
30. Li W, Chen XL, Guan SM. Efficacy and safety of olmesartan and valsartan in young and middle-aged patients. Clin Med China 2009; 25 (7): 704-5
31. Chen ZH, Gu Y, Liu QH, et al. Efficacy and safety of olmesartan medoxomil tablet in patients with mild to moderate primary hypertension. Chin J New Drugs Clin Rem 2007; 26 (6): 440-2
32. Zhang JH, Chen SC, Zhang SZ. Effect and safety of olmesartan medoxomil on treatment of essential hypertension. China Pharmacist 2008; 11 (11): 1354-5
33. Conlin Pr Fau-Spence JD, Spence Jd Fau-Williams B, Williams B Fau-Ribeiro AB, Ribeiro Ab Fau-Saito I, Saito I Fau-Benedict C, Benedict C Fau-Bunt AM, et al. Angiotensin II antagonists for hypertension: Are there differences in efficacy? Am J Hypertens 2000; 13 (4 Pt 1): 418-26
34. Ross S, Akhras K, Zhang S, et al. Discontinuation of antihypertensive drugs due to adverse events: A systematic review and meta-analysis. Pharmacotherapy 2001; 21: 940-53
35. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001 Feb 13; 103 (6): 904-12
36. Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs 2008; 68 (9): 1207-25
37. Nixon RM, Muller E, Lowy A, et al. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: A meta-analytical approach. Int J Clin Pract 2009 May; 63 (5): 766-75